Long Covid Among Kids: Numbers May Not Be Too High, But It’s a Big Risk to Ignore Its Threats

Since the Covid-19 pandemic began, it has been clear that children are less severely affected by Sars-CoV-2 than adults. Coronavirus infections in children usually do not cause symptoms, or the symptoms are mild. Nevertheless, many children infected with the omicron variant of Sars-CoV-2, whether symptomatic or asymptomatic, show health effects, even months after the virus was first detected. Recent studies have shown that long Covid is prevalent in children infected with Sars-CoV-2. India started its vaccination campaign for kids above 12 in January 2022, but we need to drastically increase this coverage to protect children from long Covid.

Why India’s 75-Day Free Booster Drive is a Smart Move and How Can it be Made Smarter

To facilitate and enhance the ongoing mass vaccination campaign for Covid-19, the government has made booster doses free for citizens above 18 years of age for 75 days, starting July 15. This announcement has come amidst the rise of Covid-19 cases across India. The decision is not only bold, but also smart. This is because a staggering 92% Indians, who are currently eligible for a third dose, have not yet taken their shots and are now late receivers. The move is targeting many objectives together: increasing affordability, improving accessibility to more groups and strengthening the trust of the people in government authorities. However, poor awareness and implementation can hinder the ultimate objective of the decision.

Vaccine Nationalism of Rich Countries: A Self-Defeating Approach With No Winners

Just a week ago, Danish officials confirmed that they will be doing away with more than 1.1 million doses of COVID-19 vaccines as their efforts to give them to other countries have failed. While on one hand, several rich countries like Denmark have vaccines in surplus, on the other hand, The Duke Global Health Innovation Centre has estimated that the majority in low-income countries will have to wait until 2023 to be vaccinated.

From Libya to Afghanistan and Syria, Vaccination Rates in War-Torn Nations Are Alarmingly Low

Fear grips the lives of people in various disputed regions around the world. Fear of several years of war and destruction and now the fear of a fatal global pandemic. The already hobbled healthcare systems have further been overwhelmed with high infection rates of Covid-19. As newer variants continue to keep coming up, the best possible way out of the situation is to get the maximum possible number of people vaccinated. However, vaccinating people in crisis zones has been fraught with difficulties thus far. Many of these areas have not even partially vaccinated one-fourth of their population. Rapid and concerted efforts in the coming months are critical to closing the vaccine distribution gap.

Current Booster Dose Policy is Not Enough. India Needs More Booster Shots To Beat The Fourth Wave

India has not begun booster doses for all adults. This is after fourteen months of initiation of the vaccination campaign. Apart from this, India has nine approved vaccines in its basket. The imprudent policy for administering booster doses is putting millions of lives at risk. According to the current policy, boosters are only open to the frontline workers and those above the age of 60. Understanding that the recent surge in cases due to the detection of new variants can be a cause of concern, India should start allocating third doses for all people.

Centre raises hopes of free COVID-19 vaccine, but benevolence can't be at the cost of the economy

This article first appeared in the Firstpost. COVID-19 has assaulted the health of people and economies. The impact on the economy has led to further stress on people’s livelihoods. This unprecedented threat to public health has not been constrained by measures taken by national and state governments. All humankind is waiting with bated breath for a COVID-19 vaccine that can set us on a course to normalcy. The human and economic cost of COVID-19 has been immense and governments are stepping up to expedite vaccine availability.Given the vaccine’s huge impact on public health, it is reasonable to expect that the government makes it available free for all. The cost of undertaking this exercise would depend on a variety of factors – the cost of manufacturing, the cost of supply chain, and the cost of administration of the vaccine. For example, nucleic acid-based vaccines have to be stored at sub-zero temperatures and are costly to make and transport. (Read more) 

COVID-19 vaccine deployment in India: Lessons we need to learn from the past

It appears that a vaccine(s) is the only way to stop COVID-19 and return the world to some semblance of normalcy. As the race inches to a close, everybody is waiting for their turn to get the vaccine and go meet their friends for a cup of coffee.However, there are several scientific hurdles that still need to be surpassed: how effective would the vaccine be across demographics? For how long will the vaccine confer immunity? Will the virus mutate, rendering the vaccine ineffective? Even if we get a combination of vaccines that answers these questions, the capacity to produce, distribute and monitor adverse events related to the vaccine are going to limit an effective vaccine rollout. Hence, it is important India identifies the vaccine demand, invests in capacity and communicates with the public to enable a smooth immunisation programme.

Lessons from COVID-19 testing

India’s response to detecting the COVID-19 outbreak was reactive, not proactive. For weeks COVID-19 testing was limited to authorised government laboratories, and available conditional on pre-determined criteria. Instead of scaling up testing capacity and aggressively test and trace, the government took a cautious approach, most likely to protect scarce testing resources. However, a strategy to ramp up both kit manufacture and early inclusion of private laboratories could have helped India’s response in containing the spread of the virus. (Read more)